Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Financings Routine +

VVT Med Expands into the Dominican Republic, Appointing Antilles Medical as Exclusive Distributor

VVT Med Advances Global Commercial Rollout of ScleroSafe with Dominican Republic Entry and Tranche 2 Financing

By The Northwire Desk — AI Analysis Jun 11, 2026 · 08:30 TSXV: NaN
Executive Summary
  • VVT Med Inc. entered a Trial Distribution and Evaluation Agreement with Antilles Medical to exclusively distribute its ScleroSafe™ device in the Dominican Republic.
  • The agreement includes an initial purchase order from the distributor and establishes a defined pathway to a five-year exclusive partnership, contingent on mutual terms after the evaluation period.
  • Antilles Medical will handle local regulatory compliance, importation, and clinical training/certification for its staff.
  • The company confirmed completion of the first tranche of a non-brokered private placement: 4,262,654 units issued at $0.25 per unit for gross proceeds of $1,065,663.50.
  • Each unit contains one common share and one-half of a warrant exercisable at $0.375 for 24 months.
  • A second tranche on identical terms is planned to close on or about July 20, 2026.
  • Net proceeds will fund expanded U.S. and global commercialization, product manufacturing, working capital, and general corporate purposes.
  • Securities carry a four-month hold period per TSXV policy.
  • The announcement follows a series of commercial milestones: a major Italian distribution deal (April 27), first patient treatments in Italy (May 26), and peer-reviewed clinical data from India (April 30).
Material Impact
  • Commercial footprint: The Dominican Republic entry extends VVT Med's Americas network, complementing existing U.S., Indian, and South Korean partnerships. The trial nature and initial purchase order suggest low near-term revenue contribution.
  • Financing: The $1.065M gross from Tranche 1 and planned Tranche 2 provide incremental runway but are dilutive. The warrant structure ($0.375 exercise) indicates continued reliance on equity markets for capital.
  • Strategic execution: The company is systematically rolling out its NT-NT sclerotherapy platform across key markets. The progression from clinical validation (India) to commercial trials (Italy, DR) aligns with standard medtech commercialization playbooks.
  • Stock impact: Routine for a TSXV-stage medical device company. The market typically prices in these sequential distribution agreements and private placements as expected operational steps rather than fundamental re-raters.
TSXV: · Price
Company Overview
  • VVT Med Inc. develops and commercializes the ScleroSafe™ System, a non-thermal, non-tumescent (NT-NT) catheter-directed sclerotherapy device for treating venous disease (varicose and spider veins).
  • The technology enables controlled sclerosant delivery with simultaneous blood aspiration, eliminating the need for thermal energy or tumescent anesthesia.
  • The device holds FDA clearance and CE marking.
  • Commercial model relies on a hybrid approach: direct sales in the U.S. (notably through Northwell Health) and exclusive distribution partnerships internationally.
  • The company is in the early commercialization phase, scaling manufacturing and clinical adoption across multiple geographies.
Read the original news release →

More from NaN

May 26, 2026 · 08:00

VVT Med Executes European Rollout with First Italian Patient Treatments Following Strong Clinical Validation

Production / Operations Apr 30, 2026 · 08:30

Clinical Validation and Distribution Expansion Drive Incremental Growth for ScleroSafe Platform

Other Apr 27, 2026 · 09:00

VVT Med Secures Italian Distribution with Investor Participation, Incremental Revenue Stream Established

M&A / Property